1 study found for:    plx7486
Show Display Options
Rank Status Study
1 Recruiting Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors
Conditions: Solid Tumors;   Untreated Pancreatic Adenocarcinoma;   Pancreatic Cancer Non-resectable;   Metastatic Pancreatic Adenocarcinoma;   Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
Interventions: Drug: PLX7486-TsOH;   Drug: gemcitabine;   Drug: nab-Paclitaxel

Indicates status has not been verified in more than two years